Galderma (SIX: GALD) is set to reinforce its leadership in injectable aesthetics at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Dubai, United Arab Emirates, from October 21-23, 2026. The company will present data from its innovative Injectable Aesthetics portfolio, underscoring its strategic commitment to meeting the evolving needs of patients and healthcare professionals.
The Swiss-based company plans a significant scientific showcase, featuring eight scientific abstracts. Complementing these presentations, Galderma will host a dedicated symposium and six specialized Meet-the-Expert sessions. These platforms will highlight the expanding benefits of its key product lines, specifically Relfydess, Sculptra, and the comprehensive Restylane range, demonstrating the breadth and depth of its offerings.
Galderma’s innovation strategy, as evidenced by the AMWC Dubai 2026 agenda, addresses a diverse array of growing needs within the aesthetic field. This includes developing solutions for menopause-related skin changes, advancing regenerative aesthetic solutions, and expanding applications for various body indications. The collective data aims to illustrate the company’s ongoing investment in research and development to maintain its competitive advantage.
This extensive participation at a prominent global industry congress signals Galderma’s continued drive to innovate and adapt its portfolio. Such strategic engagement is crucial for sustained growth and solidifying its market position in the dynamic injectable aesthetics sector.
